← All trials
NCT02282176
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2015
- Primary completion
- Jan 1, 2017
- Completion date
- Jan 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Institut National de la Santé Et de la Recherche Médicale, FranceLead sponsor
- Cardiff UniversityOverall official - principal investigator
- Cardiff UniversityCollaborator
- University of LiverpoolCollaborator
- University of NottinghamCollaborator
- University of UlmCollaborator
- Semmelweis UniversityCollaborator
- Mario Negri InstituteCollaborator
- Only For Children PharmaceuticalsCollaborator
- Advanced Biological LaboratoriesCollaborator
- SimcypCollaborator
- Karolinska InstituteCollaborator
- Erasmus University RotterdamCollaborator
- University of ParisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.